The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | SWOG S2107: encorafenib, cetuximab ± nivolumab in MSS BRAF V600E mCRC
Filippo Pietrantonio, MD, Fonzdazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses outcomes from the Phase II SWOG S2107 (NCT05308446) of encorafenib and cetuximab with or without nivolumab in patients with previously treated microsatellite stable (MSS), BRAF V600E metastatic colorectal cancer (mCRC). The addition of nivolumab did not improve survival outcomes over encorafenib and cetuximab alone. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
